Rethinking the Hydroxychloroquine Dosing and Retinopathy Screening Guidelines
Copyright © 2020 Elsevier Inc. All rights reserved..
PURPOSE: To describe the rationale for revising the hydroxychloroquine (HCQ) dosing and screening guidelines and to identify the barriers to more effective guidelines in the future.
DESIGN: Literature review.
METHODS: A PubMed query of studies on HCQ dosing and HCQ retinopathy (HCQR) screening was conducted with a selective review of the English language literature.
RESULTS: Three iterations of the American Academy of Ophthalmology HCQ dosing and HCQR screening guidelines have been published without including prescribing physicians on the writing committees. This may contribute to prescribing physicians' low adherence to the guidelines. As ancillary tests have improved, asymptomatic HCQR is being detected earlier, leading to a higher reported prevalence of HCQR and a drop in the ceiling for safe dosing. These trends put stricter constraints on prescribers and their patients, who may have had well-controlled autoimmune disease on HCQ doses that were previously considered to be below the high-risk threshold for HCQR. Indeed, stopping HCQ at the earliest sign of HCQR should be reconsidered; for cases of early HCQR, dose reduction and more intensive monitoring for retinopathy may strike a more appropriate balance between HCQ risk and benefits. A prospective study using the Diabetic Retinopathy Clinical Research Retina Network with standardized collection of data, HCQ blood levels, centralized grading of ancillary tests, and community and academic ophthalmologists would provide a stronger evidence base for future HCQ guidelines.
CONCLUSIONS: The HCQ dosing and screening guidelines should be updated and a prospective study of HCQ dosing and HCQR should be initiated with the joint efforts of ophthalmologists and prescribing physicians.
| Errataetall: |
CommentIn: Am J Ophthalmol. 2021 Feb;222:399-400. - PMID 33223050 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:219 |
|---|---|
| Enthalten in: |
American journal of ophthalmology - 219(2020) vom: 01. Nov., Seite 101-106 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Browning, David J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4QWG6N8QKH |
|---|
| Anmerkungen: |
Date Completed 21.12.2020 Date Revised 09.03.2021 published: Print-Electronic CommentIn: Am J Ophthalmol. 2021 Feb;222:399-400. - PMID 33223050 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ajo.2020.06.030 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311879144 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311879144 | ||
| 003 | DE-627 | ||
| 005 | 20231225143213.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ajo.2020.06.030 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1039.xml |
| 035 | |a (DE-627)NLM311879144 | ||
| 035 | |a (NLM)32610049 | ||
| 035 | |a (PII)S0002-9394(20)30326-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Browning, David J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rethinking the Hydroxychloroquine Dosing and Retinopathy Screening Guidelines |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.12.2020 | ||
| 500 | |a Date Revised 09.03.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Am J Ophthalmol. 2021 Feb;222:399-400. - PMID 33223050 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Inc. All rights reserved. | ||
| 520 | |a PURPOSE: To describe the rationale for revising the hydroxychloroquine (HCQ) dosing and screening guidelines and to identify the barriers to more effective guidelines in the future | ||
| 520 | |a DESIGN: Literature review | ||
| 520 | |a METHODS: A PubMed query of studies on HCQ dosing and HCQ retinopathy (HCQR) screening was conducted with a selective review of the English language literature | ||
| 520 | |a RESULTS: Three iterations of the American Academy of Ophthalmology HCQ dosing and HCQR screening guidelines have been published without including prescribing physicians on the writing committees. This may contribute to prescribing physicians' low adherence to the guidelines. As ancillary tests have improved, asymptomatic HCQR is being detected earlier, leading to a higher reported prevalence of HCQR and a drop in the ceiling for safe dosing. These trends put stricter constraints on prescribers and their patients, who may have had well-controlled autoimmune disease on HCQ doses that were previously considered to be below the high-risk threshold for HCQR. Indeed, stopping HCQ at the earliest sign of HCQR should be reconsidered; for cases of early HCQR, dose reduction and more intensive monitoring for retinopathy may strike a more appropriate balance between HCQ risk and benefits. A prospective study using the Diabetic Retinopathy Clinical Research Retina Network with standardized collection of data, HCQ blood levels, centralized grading of ancillary tests, and community and academic ophthalmologists would provide a stronger evidence base for future HCQ guidelines | ||
| 520 | |a CONCLUSIONS: The HCQ dosing and screening guidelines should be updated and a prospective study of HCQ dosing and HCQR should be initiated with the joint efforts of ophthalmologists and prescribing physicians | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Antirheumatic Agents |2 NLM | |
| 650 | 7 | |a Hydroxychloroquine |2 NLM | |
| 650 | 7 | |a 4QWG6N8QKH |2 NLM | |
| 700 | 1 | |a Yokogawa, Naoto |e verfasserin |4 aut | |
| 700 | 1 | |a Greenberg, Paul B |e verfasserin |4 aut | |
| 700 | 1 | |a Perlman, Elliot |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of ophthalmology |d 1945 |g 219(2020) vom: 01. Nov., Seite 101-106 |w (DE-627)NLM000124443 |x 1879-1891 |7 nnns |
| 773 | 1 | 8 | |g volume:219 |g year:2020 |g day:01 |g month:11 |g pages:101-106 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ajo.2020.06.030 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 219 |j 2020 |b 01 |c 11 |h 101-106 | ||